Barratt, J. Et Al. 2023. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney International , vol.103, no.2 , 391-402.

Barratt, J., Lafayette, R., Kristensen, J., Stone, A., Cattran, D., Floege, J., ... Tesar, V.(2023). Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney International , vol.103, no.2, 391-402.

Barratt, Jonathan Et Al. "Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy," Kidney International , vol.103, no.2, 391-402, 2023

Barratt, Jonathan Et Al. "Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy." Kidney International , vol.103, no.2, pp.391-402, 2023

Barratt, J. Et Al. (2023) . "Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy." Kidney International , vol.103, no.2, pp.391-402.

@article{article, author={Jonathan Barratt Et Al. }, title={Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy}, journal={Kidney International}, year=2023, pages={391-402} }